These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 33282861)

  • 1. miR-9-5p as a Regulator of the Androgen Receptor Pathway in Breast Cancer Cell Lines.
    Bandini E; Fanini F; Vannini I; Rossi T; Plousiou M; Tumedei MM; Limarzi F; Maltoni R; Fabbri F; Hrelia S; Cho WCS; Fabbri M
    Front Cell Dev Biol; 2020; 8():579160. PubMed ID: 33282861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
    Chen W; Yao G; Zhou K
    J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR.
    Zheng L; Kang Y; Zhang L; Zou W
    Cancer Biol Ther; 2020; 21(1):34-42. PubMed ID: 31736422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
    Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
    Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.
    Lindholm EM; Leivonen SK; Undlien E; Nebdal D; Git A; Caldas C; Børresen-Dale AL; Kleivi K
    Microrna; 2019; 8(2):155-165. PubMed ID: 30520388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptor.
    Casaburi I; Cesario MG; Donà A; Rizza P; Aquila S; Avena P; Lanzino M; Pellegrino M; Vivacqua A; Tucci P; Morelli C; Andò S; Sisci D
    Oncotarget; 2016 Mar; 7(11):12651-61. PubMed ID: 26862856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer.
    Tan X; Li Z; Ren S; Rezaei K; Pan Q; Goldstein AT; Macri CJ; Cao D; Brem RF; Fu SW
    Breast Cancer Res; 2019 Aug; 21(1):89. PubMed ID: 31391072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Underexpression of circulating miR-145-5p and miR-133a-3p are associated with breast cancer and immunohistochemical markers.
    García-Magallanes N; Beltran-Ontiveros SA; Leal-León EA; Luque-Ortega F; Romero-Quintana JG; Osuna-Ramirez I; Barbosa-Jasso M; Arámbula-Meraz E
    J Cancer Res Ther; 2020; 16(6):1223-1228. PubMed ID: 33342777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-379-5p inhibits the proliferation, migration, and invasion of breast cancer by targeting KIF4A.
    Yang K; Li D; Jia W; Song Y; Sun N; Wang J; Li H; Yin C
    Thorac Cancer; 2022 Jul; 13(13):1916-1924. PubMed ID: 35608059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-744/eNOS/NO axis: A novel target to halt triple negative breast cancer progression.
    El Kilany FH; Youness RA; Assal RA; Gad MZ
    Breast Dis; 2021; 40(3):161-169. PubMed ID: 33749631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
    Östling P; Leivonen SK; Aakula A; Kohonen P; Mäkelä R; Hagman Z; Edsjö A; Kangaspeska S; Edgren H; Nicorici D; Bjartell A; Ceder Y; Perälä M; Kallioniemi O
    Cancer Res; 2011 Mar; 71(5):1956-67. PubMed ID: 21343391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
    Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
    Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
    Tao L; Wu YQ; Zhang SP
    Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-143-5p Suppresses ER-Positive Breast Cancer Development by Targeting Oncogenic HMGA2.
    Mansoori B; Kiani S; Mezajin AA; Zandi P; Banaie H; Rostamzadeh D; Cho WC; Duijf PHG; Mansoori B; Baradaran B
    Clin Breast Cancer; 2023 Oct; 23(7):e480-e490.e3. PubMed ID: 37596147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-26b-5p suppresses chemoresistance in breast cancer by targeting serglycin.
    Du Q; Yuan Z; Huang X; Huang Y; Zhang J; Li R
    Anticancer Drugs; 2022 Mar; 33(3):308-319. PubMed ID: 34924500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA ZBED3-AS1 restrains breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis.
    Fu A; Yu Z; Zhang E; Song J
    Thorac Cancer; 2021 Oct; 12(20):2719-2731. PubMed ID: 34427978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-217-5p suppresses epithelial-mesenchymal transition and the NF-κB signaling pathway in breast cancer via targeting of metadherin.
    Yang L; Liu S; Yang L; Xu B; Wang M; Kong X; Song Z
    Oncol Lett; 2022 May; 23(5):162. PubMed ID: 35399330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
    Li M; Zhou Y; Xia T; Zhou X; Huang Z; Zhang H; Zhu W; Ding Q; Wang S
    Breast Cancer Res Treat; 2018 Jul; 170(2):257-270. PubMed ID: 29557526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synergy between miR-486-5p and tamoxifen causes profound cell death of tamoxifen-resistant breast cancer cells.
    Mansoori B; Najafi S; Mohammadi A; AsadollahSeraj H; Savadi P; Mansoori B; Nazari A; Mokhtarzadeh A; Roshani E; Duijf PH; Cho WC; Baradaran B
    Biomed Pharmacother; 2021 Sep; 141():111925. PubMed ID: 34323695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating miRNAs in Untreated Breast Cancer: An Exploratory Multimodality Morpho-Functional Study.
    Incoronato M; Grimaldi AM; Mirabelli P; Cavaliere C; Parente CA; Franzese M; Staibano S; Ilardi G; Russo D; Soricelli A; Catalano OA; Salvatore M
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.